The impact of the DWI-FLAIR-mismatch in the ECASS-4 trial: a post hoc analysis

Introduction: To investigate the impact of a mismatch between diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) on functional outcome in patients with acute stroke in a prolonged time window or unknown time of symptom onset randomized to intravenous thrombolysis or pla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pfaff, Johannes (VerfasserIn) , Bendszus, Martin (VerfasserIn) , Donnan, Geoffrey (VerfasserIn) , Molina, Carlos (VerfasserIn) , Leys, Didier (VerfasserIn) , Schellinger, Peter D. (VerfasserIn) , Schwab, Stefan (VerfasserIn) , Toni, Danilo (VerfasserIn) , Wahlgren, Nils (VerfasserIn) , Hacke, Werner (VerfasserIn) , Ringleb, Peter A. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2020
In: European stroke journal
Year: 2020, Jahrgang: 5, Heft: 4, Pages: 370-373
ISSN:2396-9881
DOI:10.1177/2396987320920114
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1177/2396987320920114
Verlag, lizenzpflichtig, Volltext: https://journals.sagepub.com/doi/10.1177/2396987320920114
Volltext
Verfasserangaben:Johannes Ar Pfaff, Martin Bendszus, Geoffrey Donnan, Carlos Molina, Didier Leys, Peter D. Schellinger, Stefan Schwab, Danilo Toni, Nils Wahlgren, Werner Hacke and Peter Arthur Ringleb
Beschreibung
Zusammenfassung:Introduction: To investigate the impact of a mismatch between diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) on functional outcome in patients with acute stroke in a prolonged time window or unknown time of symptom onset randomized to intravenous thrombolysis or placebo. Patients and Methods: We performed a post-hoc analysis of the European Cooperative Acute Stroke Study-4 (ECASS-4) trial. ECASS-4 was an investigator driven, phase 3, multi-center, double-blind, placebo-controlled study which randomized ischemic stroke patients presenting within 4.5 and 9h of stroke onset or unknown time-window to either rt-PA or placebo after MR-imaging. Two subgroups "no mismatch" (nMM) and "any mismatch" (aMM) were created by applying a DWI-FLAIR-mismatch criterion. We calculated frequency of nMM and aMM and performed a univariate analysis (Fisher's Test) for excellent clinical outcome (mRS 0-1) and mortality (mRS=6). Results: MR-Imaging of n=111/119 (93.2%) patients was suitable for this analysis. DWI-FLAIR mismatch was found in 49 patients (44.1%). Proportions of mismatch nMM and aMM were comparable in treatment-groups (aMM: Placebo 46.3%, Alteplase 42.1%; p=0.70). Patients with nMM showed no benefit of rt-PA-treatment (OR (95%CI) mRS 0-1: 0.95 (0.29-3.17)). Patients with aMM showed a point estimate of the odds ratio in favour of a treatment benefit of rt-PA (mRS 0-1: OR (95%CI) 2.62 (0.68-11.1)). Mortality within 90 days was not different in patients treated with rt-PA if nMM (15.2%) or aMM (12.5%) was present. Discussion: In this analysis no significant evidence, but subtle indication towards patients treated with rt-PA in a prolonged time window reaching an excellent clinical outcome if a DWI-FLAIR-mismatch is present on initial stroke MR-imaging. Conclusion: A DWI-FLAIR mismatch in the region of ischemia as imaging based surrogate parameter for patient selection for i.v. rt-PA should be strongly pursued.
Beschreibung:Gesehen am 13.07.2021
Beschreibung:Online Resource
ISSN:2396-9881
DOI:10.1177/2396987320920114